カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

治療薬モニタリングの世界市場予測（〜2025）：製品別（機器（イムノアッセイアナライザー）、消耗品）、技術別（イムノアッセイ、クロマトグラフィーMS）、薬物クラス別（抗生物質薬物、気管支拡張薬）、エンドユーザー別

【英語タイトル】Therapeutic Drug Monitoring Market by Product (Equipment (Immunoassay Analyzers), Consumables), Technology (Immunoassays, Chromatography-MS), Class of Drugs (Antibiotic Drugs, Bronchodilator Drugs), End User - Global Forecast to 2025

MarketsandMarketsが出版した調査資料（MD 4185）・商品コード：MD 4185
・発行会社（調査会社）：MarketsandMarkets
・発行日：2020年9月15日
・ページ数：230
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥722,700見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥970,900見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,189,900見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
Marketsandmarkets社は治療薬モニタリングの世界市場が2020年14億ドルから2025年20億ドルまで、年平均6.9％成長すると予測しています。本調査レポートでは、治療薬モニタリングの世界市場を調査・分析することにより、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場動向、製品別（消耗品、機器）分析、技術別（免疫学的検査、クロマトグラフィーMS）分析、薬物クラス別（抗てんかん薬、抗不整脈薬、免疫抑制薬、抗生物質、気管支拡張薬）分析、エンドユーザー別（病院研究所、商業・民間研究所、その他）分析、地域別分析、競争状況、企業概要、隣接市場など、今後の方向性を明らかに致します。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場動向
・治療薬モニタリングの世界市場規模：製品別（消耗品、機器）
・治療薬モニタリングの世界市場規模：技術別（免疫学的検査、クロマトグラフィーMS）
・治療薬モニタリングの世界市場規模：薬物クラス別（抗てんかん薬、抗不整脈薬、免疫抑制薬、抗生物質、気管支拡張薬）
・治療薬モニタリングの世界市場規模：エンドユーザー別（病院研究所、商業・民間研究所、その他）
・治療薬モニタリングの世界市場規模：地域別
・競争状況
・企業概要
・隣接市場
❖ レポートの概要 ❖

“Therapeutic drug monitoring market is projected to grow at CAGR of 6.9% from 2020 to 2025”
The global therapeutic drug monitoring market is projected to reach USD 2.0 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.9% from 2020 to 2025. The growth of the market is largely driven by factors such as the rising number of organ transplant procedures, the use of TDM across various therapeutic fields, the increasing preference for precision medicine, a growing focus on R&D related to TDM, and technological advancements in immunoassay instruments. Increased adoption in the treatment of autoimmune diseases is expected to provide a wide range of growth opportunities for players in the market.

“Consumables segment accounted for a significant share of the therapeutic drug monitoring market, by product, in 2019”
By product, the therapeutic drug monitoring market is segmented as consumables and equipment. Of all these products, consumables accounted for the largest share of the therapeutic drug monitoring market in 2019. The segment is also anticipated to grow at the fastest rate due to the repeat purchases of kits and reagents and the increasing number of immunoassay tests being performed across the globe.

“Immunoassays segment accounted for a significant share of the therapeutic drug monitoring market, by technology, in 2019”
By technology, the therapeutic drug monitoring market is segmented into immunoassays and chromatography-MS. Of all these products, immunoassays accounted for the largest share of the therapeutic drug monitoring market in 2019. The segment is also anticipated to grow at the fastest rate due to the increasing incidence of chronic and infectious diseases and technological innovation.

“Antiepileptic drugs segment accounted for the largest share of the therapeutic drug monitoring market, by class of drugs in 2019”
On the basis of class of drugs, the therapeutic drug monitoring market is segmented into antiepileptic drugs, antibiotic drugs, immunosuppressant drugs, antiarrhythmic drugs, bronchodilator drugs, psychoactive agents, and other drugs. The antiepileptic drug accounted for the largest share in 2019, due to the high complexity and heterogeneity of epilepsy, lack of biological markers or specific clinical signs aside from the frequency of seizures to assess treatment efficacy or toxicity, and the highly complex pharmacokinetics of these drugs.

“Hospital laboratories segment accounted for the largest share of the therapeutic drug monitoring market, by end user in 2019”
On the basis of end user, the therapeutic drug monitoring market is segmented into hospital laboratories, commercial & private laboratories, and other end users. Of all these end-user segments, hospital laboratories accounted for the largest share of the therapeutic drug monitoring market in 2019. The large share of this segment can be attributed to factors such as the availability of advanced healthcare facilities in hospitals and the rising incidences of chronic diseases.

“North America will continue to dominate the therapeutic drug monitoring market during the forecast period”
In 2019, North America was estimated to be the largest regional market for therapeutic drug monitoring, followed by Europe. Increasing per capita healthcare expenditure and the presence of technologically advanced healthcare infrastructure in the region, coupled with initiatives taken by different government associations, are anticipated to boost the market growth in the region.

Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (32%) , Tier 2 (42%), and Tier 3 (26%)
• By Designation: C-level (23%), Director-level (35%), and Others (42%)
• By Region: North America (42%), Europe (25%), AsiaPacific (20%), and RoW (13%).
The some of the major players operating in this market are Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), Siemens Healthineers (Germany), and Thermo Fisher Scientific (U.S.).

List of Companies Profiled in the Report
• Abbott Laboratories (U.S.)
• F. Hoffmann-La Roche (Switzerland)
• Siemens Healthineers (Germany)
• Thermo Fisher Scientific (U.S.)
• Danaher Corporation (U.S.)
• Bio-Rad Laboratories (U.S.)
• bioMérieux (France)
• BÜHLMANN Laboratories (Switzerland)
• SEKISUI MEDICAL (Japan)
• Randox Laboratories (Ireland)
• DiaSystem Scandinavia AB (Sweden)
• Cambridge Life Sciences Limited (United Kingdom)
• ARK Diagnostics, Inc. (U.S.)
• Chromsystems Instruments & Chemicals GmbH (Germany)
• Grifols (Spain)
• Exagen Inc. (U.S.)
• Theradiag (France)
• R-Biopharm AG (Germany)
• apDia Group (Belgium)
• BioTeZ Berlin-Buch GmbH (Belgium)
• Eagle Biosciences Inc. (U.S.)
• JASEM Laboratory Systems and Solutions A.S (Turkey)
• Aalto Scientific (U.S.)
• Immundiagnostik AG (Germany)
• UTAK (U.S.)

Research Coverage
This report studies the therapeutic drug monitoring market based on product, technology, class of drug, end user, and region. The report also analyzes factors (such as drivers, restraints and opportunities) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total therapeutic drug monitoring market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on therapeutic drug monitoring offered by the top 25 players in the therapeutic drug monitoring market. The report analyzes the therapeutic drug monitoring market by product, technology, class of drug, end user, and region.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the therapeutic drug monitoring market
• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the therapeutic drug monitoring market

Frequently asked questions
• What are the growth opportunities in the therapeutic drug monitoring market across major regions in the future?
• Where will all the advancements in products offered by various companies take the industry in the mid- to long-term?
• What are the various therapeutic drug monitoring product types and their respective market shares in the overall market?
• What are the new trends and advancements in the therapeutic drug monitoring market?
• What is the impact of COVID-19 on therapeutic drug monitoring market?

❖ レポートの目次 ❖

1 INTRODUCTION 36
1.1 OBJECTIVES OF THE STUDY 36
1.2 MARKET DEFINITION 36
1.2.1 INCLUSIONS & EXCLUSIONS 37
1.3 MARKET SCOPE 38
1.3.1 MARKETS COVERED 38
1.3.2 YEARS COVERED FOR THE STUDY 39
1.4 CURRENCY 39
1.5 LIMITATIONS 39
1.6 STAKEHOLDERS 40
1.7 SUMMARY OF CHANGES 40
1.8 LIMITATIONS OF THE CURRENT EDITION 40
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
FIGURE 1 RESEARCH DESIGN 41
2.1.1 SECONDARY DATA 42
2.1.1.1 Key data from secondary sources 42
2.1.2 PRIMARY DATA 43
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS 43
2.2 MARKET SIZE ESTIMATION 43
2.2.1 BOTTOM-UP APPROACH 44
FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 44
2.2.2 GROWTH FORECAST 44
FIGURE 4 TOP-DOWN APPROACH 45
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 45
FIGURE 5 DATA TRIANGULATION METHODOLOGY 45
2.4 ASSUMPTIONS FOR THE STUDY 46
3 EXECUTIVE SUMMARY 47
FIGURE 6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2020 VS. 2025 (USD MILLION) 47
FIGURE 7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2020 VS. 2025 (USD MILLION) 48
FIGURE 8 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2020 VS. 2025 (USD MILLION) 48
FIGURE 9 THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2020 VS. 2025 (USD MILLION) 49
FIGURE 10 THERAPEUTIC DRUG MONITORING MARKET, BY REGION,
2020 VS. 2025 (USD MILLION) 49
4 PREMIUM INSIGHTS 51
4.1 THERAPEUTIC DRUG MONITORING MARKET OVERVIEW 51
FIGURE 11 RISING PREFERENCE FOR PRECISION MEDICINE TO DRIVE THE TDM MARKET 51
4.2 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG 52
FIGURE 12 ANTIEPILEPTIC DRUGS WILL DOMINATE THE ASIA PACIFIC MARKET IN 2019 52
4.3 GEOGRAPHIC SNAPSHOT OF THE THERAPEUTIC DRUG MONITORING MARKET 53
FIGURE 13 CHINA TO REGISTER THE HIGHEST CAGR IN THE FORECAST PERIOD 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
FIGURE 14 THERAPEUTIC DRUG MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
5.2.1 DRIVERS 55
5.2.1.1 Importance of TDM in organ transplant procedures 55
FIGURE 15 NUMBER OF DECEASED DONORS AND TRANSPLANTS IN THE UK (APRIL 1, 2014–MARCH 31, 2018) 55
5.2.1.2 Use of TDM across various therapeutic fields 56
TABLE 1 CLASSES OF DRUGS THAT REQUIRE MONITORING 56
5.2.1.3 Increasing preference for precision medicine 57
5.2.1.4 Growing focus on R&D activities related to TDM 57
FIGURE 16 NUMBER OF RESEARCH PUBLICATIONS ON THERAPEUTIC DRUG MONITORING (2010–2019) 57
5.2.1.5 Technological advancements 58
5.2.2 RESTRAINTS 58
5.2.2.1 Requirement of high capital investments 58
5.2.2.2 Reluctance of small hospitals to offer TDM services 58
5.2.3 OPPORTUNITIES 59
5.2.3.1 Increasing adoption in the treatment of autoimmune diseases 59
5.2.4 CHALLENGES 59
5.2.4.1 Availability of alternatives to conventional TDM 59
5.2.4.2 Operational barriers faced in conducting TDM tests 60
5.3 VALUE CHAIN ANALYSIS 60
FIGURE 17 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE 61
5.4 SUPPLY CHAIN ANALYSIS 61
FIGURE 18 DIRECT DISTRIBUTION—THE PREFERRED STRATEGY FOR PROMINENT COMPANIES 62
5.5 ECOSYSTEM ANALYSIS 63
FIGURE 19 ECOSYSTEM ANALYSIS OF THE OVERALL IVD MARKET 63
5.6 IMPACT OF COVID-19 ON THE TDM MARKET 63
 
6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT 64
6.1 INTRODUCTION 65
TABLE 2 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2019 (USD MILLION) 65
TABLE 3 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 65
6.2 CONSUMABLES 65
TABLE 4 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2016–2019 (USD MILLION) 66
TABLE 5 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2020–2025 (USD MILLION) 66
6.3 EQUIPMENT 66
TABLE 6 DRUGS MONITORED USING ANALYTICAL EQUIPMENT 66
TABLE 7 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE,
2016–2019 (USD MILLION) 67
TABLE 8 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE,
2020–2025 (USD MILLION) 67
TABLE 9 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION,
2016–2019 (USD MILLION) 68
TABLE 10 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION,
2020–2025 (USD MILLION) 68
6.3.1 IMMUNOASSAY ANALYZERS 68
6.3.1.1 High efficiency of immunoassay analyzers has ensured
end-user demand 68
TABLE 11 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2016–2019 (USD MILLION) 69
TABLE 12 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2020–2025 (USD MILLION) 69
6.3.2 CHROMATOGRAPHY & MS DETECTORS 69
6.3.2.1 Technological advancements have propelled the growth
of the segment 69
TABLE 13 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY REGION, 2016–2019 (USD MILLION) 70
TABLE 14 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY AND MS DETECTORS, BY REGION, 2020–2025 (USD MILLION) 70
6.3.3 CLINICAL CHEMISTRY ANALYZERS 70
6.3.3.1 Automation to raise preference for clinical chemistry analyzers 70
TABLE 15 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2016–2019 (USD MILLION) 71
TABLE 16 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2020–2025 (USD MILLION) 71
6.4 IMPACT OF COVID-19 ON THE TDM MARKET, BY PRODUCT 71
 
7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY 72
7.1 INTRODUCTION 73
TABLE 17 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016–2019 (USD MILLION) 73
TABLE 18 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2020–2025 (USD MILLION) 73
7.2 IMMUNOASSAYS 73
TABLE 19 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION) 74
TABLE 20 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION) 74
TABLE 21 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY REGION, 2016–2019 (USD MILLION) 74
TABLE 22 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY REGION, 2020–2025 (USD MILLION) 75
7.2.1 CHEMILUMINESCENCE IMMUNOASSAYS 75
7.2.1.1 Rapid detection time and good specificity support the growth of the segment 75
TABLE 23 CLIA SYSTEMS AVAILABLE IN THE MARKET 75
TABLE 24 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY REGION,
2016–2019 (USD MILLION) 76
TABLE 25 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY REGION,
2020–2025 (USD MILLION) 76
7.2.2 FLUORESCENCE IMMUNOASSAYS 76
7.2.2.1 High operability and better sensitivity of FIAs to drive market growth 76
TABLE 26 FLUORESCENCE IMMUNOASSAYS MARKET, BY REGION,
2016–2019 (USD MILLION) 77
TABLE 27 FLUORESCENCE IMMUNOASSAYS MARKET, BY REGION,
2020–2025 (USD MILLION) 77
7.2.3 COLORIMETRIC IMMUNOASSAYS 77
7.2.3.1 Demand for colorimetric immunoassays to decline due to the rising preference for advanced equipment 77
TABLE 28 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION,
2016–2019 (USD MILLION) 78
TABLE 29 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION,
2020–2025 (USD MILLION) 78
7.2.4 RADIOIMMUNOASSAYS 78
7.2.4.1 High sensitivity in drug detection applications supports the market for radioimmunoassays 78
TABLE 30 RADIOIMMUNOASSAYS MARKET, BY REGION, 2016–2019 (USD MILLION) 79
TABLE 31 RADIOIMMUNOASSAYS MARKET, BY REGION, 2020–2025 (USD MILLION) 79
7.2.5 OTHER IMMUNOASSAYS 79
TABLE 32 OTHER IMMUNOASSAYS MARKET, BY REGION, 2016–2019 (USD MILLION) 80
TABLE 33 OTHER IMMUNOASSAYS MARKET, BY REGION, 2020–2025 (USD MILLION) 80
 
7.3 CHROMATOGRAPHY-MS 80
TABLE 34 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS,
BY TYPE, 2016–2019 (USD MILLION) 81
TABLE 35 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS,
BY TYPE, 2025–2025 (USD MILLION) 81
7.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY 81
7.3.1.1 High accuracy supports demand for LC-MS 81
TABLE 36 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2016–2019 (USD MILLION) 82
TABLE 37 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2025–2025 (USD MILLION) 82
7.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY 82
7.3.2.1 Drawbacks of GC-MS challenge market growth 82
TABLE 38 GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2016–2019 (USD MILLION) 83
TABLE 39 GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2020–2025 (USD MILLION) 83
8 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG 84
8.1 INTRODUCTION 85
TABLE 40 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2016–2019 (USD MILLION) 85
TABLE 41 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2020–2025 (USD MILLION) 85
8.2 ANTIEPILEPTIC DRUGS 86
8.2.1 HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE THE GROWTH OF THE SEGMENT 86
TABLE 42 LIMITATIONS OF TDM OF NEWER ANTIEPILEPTIC DRUGS 86
TABLE 43 ANTIEPILEPTIC DRUG MONITORING MARKET, BY REGION,
2016–2019 (USD MILLION) 87
TABLE 44 ANTIEPILEPTIC DRUG MONITORING MARKET, BY REGION,
2020–2025 (USD MILLION) 87
8.3 ANTIARRHYTHMIC DRUGS 87
8.3.1 INCREASING INCIDENCE OF HEART DISORDERS TO SUPPORT SEGMENT GROWTH 87
TABLE 45 ANTIARRHYTHMIC DRUG MONITORING MARKET, BY REGION,
2016–2019 (USD MILLION) 88
TABLE 46 ANTIARRHYTHMIC DRUG MONITORING MARKET, BY REGION,
2020–2025 (USD MILLION) 88
8.4 IMMUNOSUPPRESSANT DRUGS 88
8.4.1 IMMUNOSUPPRESSANT DEMAND HAS RISEN DUE TO AN INCREASE IN ORGAN TRANSPLANTATION PROCEDURES 88
TABLE 47 IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY REGION,
2016–2019 (USD MILLION) 89
TABLE 48 IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY REGION,
2020–2025 (USD MILLION) 89
 
8.5 ANTIBIOTIC DRUGS 89
8.5.1 TECHNOLOGICAL ADVANCEMENTS TO PROPEL THE DEMAND FOR ANTIBIOTIC DRUG MONITORING 89
TABLE 49 ANTIBIOTIC DRUG MONITORING MARKET, BY REGION,
2016–2019 (USD MILLION) 90
TABLE 50 ANTIBIOTIC DRUG MONITORING MARKET, BY REGION,
2020–2025 (USD MILLION) 90
8.6 BRONCHODILATOR DRUGS 90
8.6.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES WILL ENSURE DEMAND FOR BRONCHODILATOR DRUG MONITORING 90
TABLE 51 BRONCHODILATOR DRUG MONITORING MARKET, BY REGION,
2016–2019 (USD MILLION) 91
TABLE 52 BRONCHODILATOR DRUG MONITORING MARKET, BY REGION,
2020–2025 (USD MILLION) 91
8.7 PSYCHOACTIVE DRUGS 91
8.7.1 RISING CASES OF MENTAL ILLNESS TO DRIVE MARKET GROWTH 91
TABLE 53 PSYCHOACTIVE DRUG MONITORING MARKET, BY REGION,
2016–2019 (USD MILLION) 92
TABLE 54 PSYCHOACTIVE DRUG MONITORING MARKET, BY REGION,
2020–2025 (USD MILLION) 92
8.8 OTHER DRUGS 92
TABLE 55 OTHER DRUG MONITORING MARKET, BY REGION,
2016–2019 (USD MILLION) 93
TABLE 56 OTHER DRUG MONITORING MARKET, BY REGION,
2020–2025 (USD MILLION) 93
8.9 IMPACT OF COVID-19 ON THE TDM MARKET, BY CLASS OF DRUG 93
9 THERAPEUTIC DRUG MONITORING MARKET, BY END USER 94
9.1 INTRODUCTION 95
TABLE 57 THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2019 (USD MILLION) 95
TABLE 58 THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2020–2025 (USD MILLION) 95
9.2 HOSPITAL LABORATORIES 96
9.2.1 HOSPITAL LABS HOLD THE LARGEST SHARE OF THE END-USER MARKET 96
TABLE 59 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2016-2019 (USD MILLION) 96
TABLE 60 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2025–2025 (USD MILLION) 96
9.3 COMMERCIAL & PRIVATE LABORATORIES 97
9.3.1 EXTENSIVE TEST MENUS OF COMMERCIAL & PRIVATE LABS SUPPORT DEMAND FOR THEIR SERVICES 97
TABLE 61 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2016-2019 (USD MILLION) 97
TABLE 62 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2025–2025 (USD MILLION) 97
9.4 OTHER END USERS 98
TABLE 63 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS,
BY REGION, 2016–2019 (USD MILLION) 98
TABLE 64 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS,
BY REGION, 2020–2025 (USD MILLION) 98
9.5 IMPACT OF COVID-19 ON THE TDM MARKET, BY END USER 98
10 THERAPEUTIC DRUG MONITORING MARKET, BY REGION 99
10.1 INTRODUCTION 100
TABLE 65 THERAPEUTIC DRUG MONITORING MARKET, BY REGION,
2016–2019 (USD MILLION) 100
TABLE 66 THERAPEUTIC DRUG MONITORING MARKET, BY REGION,
2020–2025 (USD MILLION) 100
10.2 NORTH AMERICA 101
FIGURE 20 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT 102
TABLE 67 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2016–2019 (USD MILLION) 103
TABLE 68 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020–2025 (USD MILLION) 103
TABLE 69 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 103
TABLE 70 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION) 103
TABLE 71 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2019 (USD MILLION) 104
TABLE 72 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2025 (USD MILLION) 104
TABLE 73 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET,
BY TECHNOLOGY, 2016–2019 (USD MILLION) 104
TABLE 74 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET,
BY TECHNOLOGY, 2020–2025 (USD MILLION) 105
TABLE 75 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION) 105
TABLE 76 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION) 105
TABLE 77 NORTH AMERICA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-
MS MARKET, BY TYPE, 2016–2019 (USD MILLION) 106
TABLE 78 NORTH AMERICA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-
MS MARKET, BY TYPE, 2020–2025 (USD MILLION) 106
TABLE 79 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET,
BY CLASS OF DRUG, 2016–2019 (USD MILLION) 106
TABLE 80 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET,
BY CLASS OF DRUG, 2020–2025 (USD MILLION) 107
TABLE 81 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET,
BY END USER, 2016–2019 (USD MILLION) 107
TABLE 82 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET,
BY END USER, 2020–2025 (USD MILLION) 107
10.2.1 US 108
10.2.1.1 Awareness regarding precision medicine to propel the TDM market in the US 108
TABLE 83 NUMBER OF TESTS COVERED BY MEDICARE FOR EACH DRUG CLASS 108
TABLE 84 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2019 (USD MILLION) 109
TABLE 85 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 109
TABLE 86 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016–2019 (USD MILLION) 109
TABLE 87 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2020–2025 (USD MILLION) 109
TABLE 88 US: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION) 110
TABLE 89 US: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION) 110
TABLE 90 US: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET,
BY TYPE, 2016–2019 (USD MILLION) 110
TABLE 91 US: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET,
BY TYPE, 2020–2025 (USD MILLION) 111
TABLE 92 US: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2016–2019 (USD MILLION) 111
TABLE 93 US: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2020–2025 (USD MILLION) 111
TABLE 94 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2019 (USD MILLION) 112
TABLE 95 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2020–2025 (USD MILLION) 112
10.2.2 CANADA 112
10.2.2.1 Availability of funding for research to offer growth opportunities in the Canadian market 112
TABLE 96 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2019 (USD MILLION) 113
TABLE 97 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 113
TABLE 98 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION) 114
TABLE 99 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION) 114
TABLE 100 CANADA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016–2019 (USD MILLION) 114
TABLE 101 CANADA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2020–2025 (USD MILLION) 115
TABLE 102 CANADA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION) 115
TABLE 103 CANADA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION) 115
TABLE 104 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION) 116
TABLE 105 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION) 116
TABLE 106 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2019 (USD MILLION) 116
TABLE 107 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2020–2025 (USD MILLION) 117
10.3 EUROPE 117
TABLE 108 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY,
2016–2019 (USD MILLION) 117
TABLE 109 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY,
2020–2025 (USD MILLION) 118
TABLE 110 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2019 (USD MILLION) 118
TABLE 111 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 118
TABLE 112 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2019 (USD MILLION) 119
TABLE 113 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2025 (USD MILLION) 119
TABLE 114 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION) 119
TABLE 115 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION) 120
TABLE 116 EUROPE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016–2019 (USD MILLION) 120
TABLE 117 EUROPE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2020–2025 (USD MILLION) 120
TABLE 118 EUROPE: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION) 121
TABLE 119 EUROPE: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION) 121
TABLE 120 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION) 121
TABLE 121 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION) 122
TABLE 122 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2019 (USD MILLION) 122
TABLE 123 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2020–2025 (USD MILLION) 122
10.3.1 GERMANY 123
10.3.1.1 Prevalence of chronic medical conditions such as cancer and diabetes will support the growth of the market in Germany 123
TABLE 124 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2019 (USD MILLION) 123
TABLE 125 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 123
TABLE 126 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION) 124
TABLE 127 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION) 124
TABLE 128 GERMANY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016–2019 (USD MILLION) 124
TABLE 129 GERMANY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2020–2025 (USD MILLION) 125
TABLE 130 GERMANY: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION) 125
TABLE 131 GERMANY: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION) 125
TABLE 132 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION) 126
TABLE 133 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION) 126
TABLE 134 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION) 126
TABLE 135 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION) 127
10.3.2 ITALY 127
10.3.2.1 Rising incidences of cancer to drive demand for TDM in Italy 127
TABLE 136 ITALY: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025 128
TABLE 137 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2019 (USD MILLION) 128
TABLE 138 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 128
TABLE 139 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016–2019 (USD MILLION) 128
TABLE 140 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2020–2025 (USD MILLION) 129
TABLE 141 ITALY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION) 129
TABLE 142 ITALY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION) 129
TABLE 143 ITALY: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION) 130
TABLE 144 ITALY: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION) 130
TABLE 145 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION) 130
TABLE 146 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION) 131
TABLE 147 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2019 (USD MILLION) 131
TABLE 148 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2020–2025 (USD MILLION) 131

10.3.3 FRANCE 132
10.3.3.1 Awareness regarding the benefits of TDM to accelerate its demand across various therapeutic applications 132
TABLE 149 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2019 (USD MILLION) 132
TABLE 150 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 133
TABLE 151 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION) 133
TABLE 152 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION) 133
TABLE 153 FRANCE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016–2019 (USD MILLION) 134
TABLE 154 FRANCE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2020–2025 (USD MILLION) 134
TABLE 155 FRANCE: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION) 134
TABLE 156 FRANCE: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION) 135
TABLE 157 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION) 135
TABLE 158 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION) 135
TABLE 159 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2019 (USD MILLION) 136
TABLE 160 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2020–2025 (USD MILLION) 136
10.3.4 SPAIN 136
10.3.4.1 Adoption of technologically advanced immunoassays has boosted the market in Spain 136
TABLE 161 SPAIN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025 137
TABLE 162 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2019 (USD MILLION) 137
TABLE 163 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 137
TABLE 164 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016–2019 (USD MILLION) 138
TABLE 165 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2020–2025 (USD MILLION) 138
TABLE 166 SPAIN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016–2019 (USD MILLION) 138
TABLE 167 SPAIN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2020–2025 (USD MILLION) 139
TABLE 168 SPAIN: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION) 139
TABLE 169 SPAIN: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION) 139
TABLE 170 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION) 140
TABLE 171 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION) 140
TABLE 172 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2019 (USD MILLION) 140
TABLE 173 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2020–2025 (USD MILLION) 141
10.3.5 UK 141
10.3.5.1 Increasing cases of chronic diseases to drive the growth of the TDM market 141
TABLE 174 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2019 (USD MILLION) 142
TABLE 175 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 142
TABLE 176 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016–2019 (USD MILLION) 142
TABLE 177 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2020–2025 (USD MILLION) 142
TABLE 178 UK: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION) 143
TABLE 179 UK: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION) 143
TABLE 180 UK: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET,
BY TYPE, 2016–2019 (USD MILLION) 143
TABLE 181 UK: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET,
BY TYPE, 2020–2025 (USD MILLION) 144
TABLE 182 UK: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2016–2019 (USD MILLION) 144
TABLE 183 UK: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2020–2025 (USD MILLION) 144
TABLE 184 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2019 (USD MILLION) 145
TABLE 185 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2020–2025 (USD MILLION) 145
10.3.6 REST OF EUROPE 145
TABLE 186 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2019 (USD MILLION) 145
TABLE 187 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 146
TABLE 188 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016–2019 (USD MILLION) 146
TABLE 189 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2020–2025 (USD MILLION) 146
TABLE 190 ROE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION) 147
TABLE 191 ROE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION) 147
TABLE 192 ROE: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET,
BY TYPE, 2016–2019 (USD MILLION) 147
TABLE 193 ROE: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET,
BY TYPE, 2020–2025 (USD MILLION) 148
TABLE 194 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION) 148
TABLE 195 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION) 148
TABLE 196 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2019 (USD MILLION) 149
TABLE 197 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2020–2025 (USD MILLION) 149
10.4 ASIA PACIFIC 149
FIGURE 21 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT 150
TABLE 198 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2016–2019 (USD MILLION) 151
TABLE 199 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020–2025 (USD MILLION) 151
TABLE 200 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION) 151
TABLE 201 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION) 152
TABLE 202 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET,
BY TYPE, 2016–2019 (USD MILLION) 152
TABLE 203 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET,
BY TYPE, 2020–2025 (USD MILLION) 152
TABLE 204 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION) 153
TABLE 205 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION) 153
TABLE 206 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION) 153
TABLE 207 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION) 154
TABLE 208 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION) 154
TABLE 209 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION) 154
TABLE 210 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION) 155
TABLE 211 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION) 155
TABLE 212 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION) 155
TABLE 213 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION) 156
10.4.1 JAPAN 156
10.4.1.1 Japan holds the largest share of the APAC market for therapeutic drug monitoring 156
TABLE 214 JAPAN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025 156
TABLE 215 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2019 (USD MILLION) 157
TABLE 216 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 157
TABLE 217 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016–2019 (USD MILLION) 157
TABLE 218 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2020–2025 (USD MILLION) 157
TABLE 219 JAPAN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016–2019 (USD MILLION) 158
TABLE 220 JAPAN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2020–2025 (USD MILLION) 158
TABLE 221 JAPAN: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION) 158
TABLE 222 JAPAN: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION) 159
TABLE 223 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION) 159
TABLE 224 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION) 159
TABLE 225 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2019 (USD MILLION) 160
TABLE 226 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2020–2025 (USD MILLION) 160
10.4.2 CHINA 160
10.4.2.1 Rising number of organ transplants in the country will drive the growth of the TDM market 160
TABLE 227 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2019 (USD MILLION) 161
TABLE 228 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 161
TABLE 229 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016–2019 (USD MILLION) 161
TABLE 230 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2020–2025 (USD MILLION) 161
TABLE 231 CHINA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016–2019 (USD MILLION) 162
TABLE 232 CHINA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2020–2025 (USD MILLION) 162
TABLE 233 CHINA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION) 162
TABLE 234 CHINA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION) 163
TABLE 235 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION) 163
TABLE 236 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION) 163
TABLE 237 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2019 (USD MILLION) 164
TABLE 238 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2020–2025 (USD MILLION) 164
10.4.3 INDIA 164
10.4.3.1 Rising incidence of cancer to propel market growth 164
TABLE 239 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2019 (USD MILLION) 165
TABLE 240 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 165
TABLE 241 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016–2019 (USD MILLION) 165
TABLE 242 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2020–2025 (USD MILLION) 166
TABLE 243 INDIA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016–2019 (USD MILLION) 166
TABLE 244 INDIA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2020–2025 (USD MILLION) 166
TABLE 245 INDIA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION) 167
TABLE 246 INDIA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION) 167
TABLE 247 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION) 167
TABLE 248 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION) 168
TABLE 249 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2019 (USD MILLION) 168
TABLE 250 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2020–2025 (USD MILLION) 168
10.4.4 ROAPAC 169
TABLE 251 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2019 (USD MILLION) 169
TABLE 252 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 169
TABLE 253 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION) 170
TABLE 254 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION) 170
TABLE 255 ROAPAC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016–2019 (USD MILLION) 170
TABLE 256 ROAPAC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2020–2025 (USD MILLION) 171
TABLE 257 ROAPAC: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION) 171
TABLE 258 ROAPAC: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION) 171
TABLE 259 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION) 172
TABLE 260 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION) 172
TABLE 261 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2019 (USD MILLION) 172
TABLE 262 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2020–2025 (USD MILLION) 173
10.5 REST OF THE WORLD 173
10.5.1 ROW ACCOUNTS FOR THE SMALLEST SHARE OF THE OVERALL MARKET BUT IS EXPECTED TO SEE HIGH GROWTH 173
TABLE 263 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2019 (USD MILLION) 173
TABLE 264 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 174
TABLE 265 ROW: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2019 (USD MILLION) 174
TABLE 266 ROW: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2025 (USD MILLION) 174
TABLE 267 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016–2019 (USD MILLION) 175
TABLE 268 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2020–2025 (USD MILLION) 175
TABLE 269 ROW: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION) 175
TABLE 270 ROW: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION) 176
TABLE 271 ROW: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION) 176
TABLE 272 ROW: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION) 176
TABLE 273 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION) 177
TABLE 274 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION) 177
TABLE 275 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2019 (USD MILLION) 177
TABLE 276 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2020–2025 (USD MILLION) 178
10.6 IMPACT OF COVID-19 ON THE TDM MARKET, BY REGION 178
11 COMPETITIVE LANDSCAPE 179
11.1 OVERVIEW 179
FIGURE 22 KEY DEVELOPMENTS IN THE THERAPEUTIC DRUG MONITORING MARKET FROM JANUARY 2017–JULY 2020 179
FIGURE 23 MARKET EVOLUTION FRAMEWORK: JANUARY 2017 TO JULY 2020 180
11.2 MARKET SHARE ANALYSIS, 2019 180
FIGURE 24 THERAPEUTIC DRUG MONITORING MARKET SHARE ANALYSIS (2019) 180
11.3 COMPETITIVE SCENARIO 181
11.3.1 PRODUCT APPROVALS 181
TABLE 277 KEY PRODUCT APPROVALS 181
11.3.2 PRODUCT LAUNCHES 182
TABLE 278 KEY PRODUCT LAUNCHES 182
11.3.3 AGREEMENTS 182
TABLE 279 KEY AGREEMENTS 182
11.3.4 EXPANSIONS 183
TABLE 280 KEY EXPANSIONS 183
11.3.5 ACQUISITIONS 183
TABLE 281 KEY ACQUISITIONS 183
11.4 COMPETITIVE LEADERSHIP MAPPING (2019) 184
11.4.1 STARS 184
11.4.2 EMERGING LEADERS 184
11.4.3 PERVASIVE COMPANIES 184
11.4.4 PARTICIPANTS 184
FIGURE 25 VENDOR COMPARISON MATRIX: THERAPEUTIC DRUG MONITORING MARKET 185
12 COMPANY PROFILES 186
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 ABBOTT LABORATORIES 186
FIGURE 26 ABBOTT LABORATORIES: COMPANY SNAPSHOT 186
12.2 THERMO FISHER SCIENTIFIC 188
FIGURE 27 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT 188
12.3 F. HOFFMANN-LA ROCHE 191
FIGURE 28 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT 191
12.4 SIEMENS HEALTHINEERS 194
FIGURE 29 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT 194
12.5 DANAHER CORPORATION 197
FIGURE 30 DANAHER CORPORATION: COMPANY SNAPSHOT 197
12.6 BIO-RAD LABORATORIES 199
FIGURE 31 BIO-RAD LABORATORIES: COMPANY SNAPSHOT 199
12.7 BIOMÉRIEUX 202
FIGURE 32 BIOMÉRIEUX: COMPANY SNAPSHOT 202
12.8 THERADIAG 204
FIGURE 33 THERADIAG: COMPANY SNAPSHOT 204
12.9 GRIFOLS 206
FIGURE 34 GRIFOLS: COMPANY SNAPSHOT 206
12.10 BÜHLMANN LABORATORIES 208
12.11 SEKISUI MEDICAL 209
12.12 RANDOX LABORATORIES 210
12.13 DIASYSTEM SCANDINAVIA 212
12.14 CAMBRIDGE LIFE SCIENCES 213
12.15 ARK DIAGNOSTICS 214
12.16 CHROMSYSTEMS INSTRUMENTS & CHEMICALS 216
12.17 EXAGEN 218
FIGURE 35 EXAGEN: COMPANY SNAPSHOT 218
12.18 R-BIOPHARM 220
12.19 APDIA GROUP 221
12.20 BIOTEZ BERLIN BUCH 221
12.21 EAGLE BIOSCIENCES 222
12.22 JASEM LABORATORY SYSTEMS AND SOLUTIONS 224
12.23 AALTO SCIENTIFIC 224
12.24 IMMUNDIAGNOSTIK 225
12.25 UTAK 226
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
13 ADJACENT MARKETS 227
13.1 INTRODUCTION 227
13.2 IMMUNOASSAY MARKET 227
13.2.1 MARKET DEFINITION 227
13.2.2 LIMITATIONS 227
13.2.3 MARKET OVERVIEW 227
13.2.3.1 Introduction 227
13.2.3.2 Technological advancements 228
13.2.3.3 Growth in the biotechnology and pharmaceutical industry 228
13.3 IMMUNOASSAY MARKET, BY PRODUCT & SERVICE 228
TABLE 282 IMMUNOASSAY MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 228
13.4 IMMUNOASSAY MARKET, BY PLATFORM 229
TABLE 283 IMMUNOASSAY MARKET, BY PLATFORM, 2016–2023 (USD MILLION) 229
13.5 IMMUNOASSAY MARKET, BY TECHNOLOGY 229
TABLE 284 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 230
13.6 IMMUNOASSAY MARKET, BY SPECIMEN TYPE 230
TABLE 285 IMMUNOASSAY MARKET, BY SPECIMEN TYPE, 2016–2023 (USD MILLION) 230
13.7 IMMUNOASSAY MARKET, BY APPLICATION 231
TABLE 286 IMMUNOASSAY MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 231
13.8 IMMUNOASSAY MARKET, BY END USER 231
TABLE 287 IMMUNOASSAY MARKET, BY END USER, 2016–2023 (USD MILLION) 232
13.9 IMMUNOASSAY MARKET, BY REGION 232
TABLE 288 IMMUNOASSAY MARKET, BY REGION, 2016–2023 (USD MILLION) 232
 
14 APPENDIX 233
14.1 INSIGHTS FROM INDUSTRY EXPERTS 233
14.2 DISCUSSION GUIDE 234
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 237
14.4 AVAILABLE CUSTOMIZATIONS 239
14.5 RELATED REPORTS 240
14.6 AUTHOR DETAILS 241

★調査レポート[治療薬モニタリングの世界市場予測（〜2025）：製品別（機器（イムノアッセイアナライザー）、消耗品）、技術別（イムノアッセイ、クロマトグラフィーMS）、薬物クラス別（抗生物質薬物、気管支拡張薬）、エンドユーザー別] (コード：MD 4185)販売に関する免責事項を必ずご確認ください。
★調査レポート[治療薬モニタリングの世界市場予測（〜2025）：製品別（機器（イムノアッセイアナライザー）、消耗品）、技術別（イムノアッセイ、クロマトグラフィーMS）、薬物クラス別（抗生物質薬物、気管支拡張薬）、エンドユーザー別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の治療薬物モニタリング（TDM）市場（～2026年）：製品別（消耗品、機器-イムノアッセイアナライザー、クロマトグラフィー＆MS検出器、臨床化学アナライザー）、技術別、薬剤分類別、エンドユーザー別、地域別
    MD4185 / MarketsandMarkets / 2022年2月1日 / マーケッツアンドマーケッツ社は、世界の治療薬物モニタリング（TDM）市場規模が、2020年16億ドルから2026年27億ドルまで年平均9.4％成長すると予測しています。本調査資料では、治療薬物モニタリング（TDM）の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別（消耗品、機器）分析、技術別（イムノアッセイ、クロマトグラフィー-MS）分析、薬剤分類別（抗てんかん薬、抗不整脈薬、免疫抑制薬、抗生物質、気管支拡張薬）分析、エンドユーザー別（病院研究室、商業・民間研究室、その他）分析、地域別分析、競争状況、企業情報などの項目を掲載しています。 ・イントロダクション...
  • 世界の慢性閉塞性肺疾患（COPD）治療薬市場2022-2031：薬物クラス別（併用療法、気管支拡張薬、副腎皮質ステロイド、ホスホジエステラーゼ4型阻害剤、去痰薬、その他）
    TMR23JN036 / Transparency Market Research / 2022年10月31日 / Transparency Market...
  • 世界の体外診断/IVD市場（～2026年）：製品・サービス別（機器、キット）、技術別（イムノアッセイ、MDx、血液、尿検査）、用途別（糖尿病、腫瘍、心臓病、腎臓病、感染症）、エンドユーザー別（病院）
    MD3609-22 / MarketsandMarkets / 2022年3月9日 / マーケッツアンドマーケッツ社は、世界の体外診断/IVD市場規模が、2021年982億ドルから2026年1,131億ドルまで年平均2.9％成長すると予測しています。本調査レポートは、体外診断/IVDの世界市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、産業インサイト、製品・サービス別（試薬＆キット、機器、データ管理ソフトウェア、サービス）分析、技術別（イムノアッセイ、臨床化学、分子診断、血液、微生物）分析、用途別（糖尿病、腫瘍、心臓病、薬物検査/薬理ゲノミクス、その他）分析、エンドユーザー別（病院、臨床研究室、POC検査センター、学術機関、その他）分析、地域別分析、競争状況、企業情報など、以下の構成でまとめております。 ・イントロダクション...
  • 世界の薬物スクリーニング市場（～2026年）：製品（消耗品、尿検査デバイス、分析、飲酒、クロマトグラフィー、イムノアッセイ）＆サービス別、サンプルタイプ別（尿、呼気）、エンドユーザー別（職場、研究所、刑事司法、病院）
    MD3239 / MarketsandMarkets / 2022年1月11日 / マーケッツアンドマーケッツ社は、世界の薬物スクリーニング市場規模が2021年53億ドルから2026年116億ドルまで、年平均16.8％成長すると予測しています。本調査レポートは、薬物スクリーニングの世界市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品・サービス別（薬物スクリーニングサービス、薬物スクリーニング製品）分析、サンプルタイプ別（尿、呼気、口腔液、毛髪、その他）分析、エンドユーザー別（職場、刑事司法・法執行機関、病院、薬物治療センター、個人）分析、地域別分析、競争状況、企業情報など、以下の構成でまとめております。 ・イントロダクション...
  • 世界の気管支炎治療市場2022年-2028年：薬剤クラス別（抗生物質、抗炎症薬、気管支拡張薬、その他）、エンドユーザー別、種類別、地域別
    BZW22JN076 / Bizwit Research & Consulting / 2022年5月25日 / Bizwit Research社は、世界の気管支炎治療市場規模が2021年5,921.89百万ドルに達し、2022年から2028年までに6.64％成長すると予想しています。本市場調査資料では、気管支炎治療の世界市場を広く調査・分析し、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析（新型コロナウイルス感染症の影響）、薬剤クラス別（抗生物質、抗炎症薬、気管支拡張薬、その他）分析、エンドユーザー別（病院薬局、小売薬局、その他）分析、種類別（急性気管支炎、慢性気管支炎）分析、地域別分析、競争分析、調査プロセスなど、以下の構成でまとめました。本市場調査資料では、AstraZeneca...

    • ◆H&Iグローバルリサーチのお客様（例）◆